-
公开(公告)号:US12128062B2
公开(公告)日:2024-10-29
申请号:US17258544
申请日:2019-08-14
IPC分类号: C12N15/11 , A61K31/16 , A61K31/19 , A61K31/7004 , A61K31/7105 , A61K47/54 , C12N15/113
CPC分类号: A61K31/7105 , A61K31/16 , A61K31/19 , A61K31/7004 , A61K47/543 , A61K47/549 , C12N15/1138 , C12N2310/11 , C12N2310/346
摘要: Methods of alleviating or prophylactically blocking pain through the alteration of certain metabolic pathways in a subject experiencing pain or expecting to experience pain are disclosed. In particular, methods of increasing the amount of the neutral amino acid transporter ASCT2 in neurons are disclosed. Increased glutamine uptake by neurons leads to reduced extrusion of lactate and protons into the extracellular space and by extension, reduced sensitization of the neurons. Reduced sensitization of the neurons lessens the feeling of pain in the subject.
-
公开(公告)号:US12128061B2
公开(公告)日:2024-10-29
申请号:US16147844
申请日:2018-09-30
申请人: Vycellix, Inc.
发明人: Evren Alici
IPC分类号: A61K31/7105 , A61K9/127 , A61K31/7115 , A61K38/20 , A61P35/00 , C07K16/28 , C07K16/40 , C12N15/117
CPC分类号: A61K31/7105 , A61K9/1271 , A61K31/7115 , A61K38/2013 , A61P35/00 , C07K16/28 , C07K16/40 , C12N15/117 , C12N2310/17 , C12N2310/531 , C12N2320/30 , C12N2320/31 , C12N2320/32 , A61K31/7115 , A61K2300/00
摘要: The present invention comprises Rig I agonists for enhancing the effects of cytotoxic cells and stem Cells. The Rig I agonists can be used in vivo as small molecule therapeutics or in vitro to enhance cells for adoptive cell transfer. Applications include cancer therapy, immune system enhancement, chronic viral infection and treatment of viral induced inflammation and enhancement of virus based therapies.
-
公开(公告)号:US12122848B2
公开(公告)日:2024-10-22
申请号:US17365723
申请日:2021-07-01
发明人: Omid Khorram , Tsai-Der Chuang
IPC分类号: C07K16/40 , A61K31/4188 , A61K31/4245 , A61K31/4439 , A61K31/47 , A61K31/7105 , A61P15/00 , A61P19/04
CPC分类号: C07K16/40 , A61K31/4188 , A61K31/4245 , A61K31/4439 , A61K31/47 , A61K31/7105 , A61P15/00 , A61P19/04
摘要: The present disclosure relates generally to compositions and methods for treating fibroid in a patient in need thereof, which entails administering to the patient an effective amount of an agent that inhibits the expression or activity of TDO2 or IDO1.
-
4.
公开(公告)号:US20240342207A1
公开(公告)日:2024-10-17
申请号:US18294680
申请日:2022-08-02
发明人: Liuqing YANG , Chunru LIN , Sergey D. EGRANOV , Yajuan LI
IPC分类号: A61K31/7105 , A61K48/00 , A61P3/00 , C12N15/11
CPC分类号: A61K31/7105 , A61K48/0075 , A61P3/00 , C12N15/11 , C12N2310/315 , C12N2310/322 , C12N2310/3517
摘要: This disclosure provides modified nucleic acids and compositions thereof that are able to mimic the human HULC lncRNA and/or the mouse Pair lncRNA and enhance phenylalanine hydroxylase enzyme (PAH)-substrate binding affinity, PAH-cofactor binding affinity, and/or PAH enzymatic conversion of phenylalanine to tyrosine. Also provided are methods of using the modified nucleic acids and compositions thereof to treat subjects having or suspected of having phenylketonuria and hyperphenylalaninemia.
-
公开(公告)号:US12116574B2
公开(公告)日:2024-10-15
申请号:US17474949
申请日:2021-09-14
发明人: William A. Muller , Bita F. Cyrus
IPC分类号: C12N15/113 , A61K31/7105 , A61K31/713 , A61K38/00 , A61K38/46 , A61K45/06
CPC分类号: C12N15/113 , A61K31/7105 , A61K31/713 , A61K38/005 , A61K38/46 , A61K45/06 , C12Y306/04004 , C12Y306/04005 , C12N2310/14 , C12N2310/531 , A61K31/713 , A61K2300/00 , A61K31/7105 , A61K2300/00
摘要: Provided herein are compositions and methods for the inhibition of endothelial cell kinesin light chain 1, variant 1 (KLC1C) expression and/or activity, and treatment or prevention of inflammation therewith.
-
公开(公告)号:US12115230B2
公开(公告)日:2024-10-15
申请号:US17918092
申请日:2021-04-09
发明人: Alexandra Chadwick , Kallanthottathil G. Rajeev , Ellen Rohde , Christopher Cheng , Caroline Reiss
IPC分类号: C12N15/11 , A61K9/127 , A61K31/7105 , A61K38/46 , A61K48/00 , C07K14/515 , C12N9/22 , C12N15/113 , C12N15/90
CPC分类号: A61K48/0066 , A61K9/127 , A61K31/7105 , A61K38/465 , C07K14/515 , C12N9/22 , C12N15/11 , C12N15/113 , C12N15/907 , C07K2319/09 , C07K2319/80 , C12N2310/20 , C12N2310/315 , C12N2310/321 , C12N2310/331 , C12N2310/335 , C12N2310/344 , C12N2310/3521 , C12N2800/80
摘要: Provided herein are compositions for gene modification or editing and methods of using same to treat or prevent certain conditions. Specific compositions and methods capable of safely and effectively editing gene targets expressed in the liver to durably lower LDL-C thereby treating a leading cause of cardiovascular disease are disclosed.
-
公开(公告)号:US20240327838A1
公开(公告)日:2024-10-03
申请号:US18492683
申请日:2023-10-23
IPC分类号: C12N15/113 , A61K9/00 , A61K31/404 , A61K31/47 , A61K31/7105 , A61K31/713 , A61M11/00 , A61P11/00
CPC分类号: C12N15/113 , A61K9/0019 , A61K9/0075 , A61K9/0078 , A61K31/404 , A61K31/47 , A61K31/7105 , A61K31/713 , A61P11/00 , A61M11/005 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/3231 , C12N2310/3341 , C12N2310/341 , C12N2310/345 , C12N2310/346 , C12N2320/31 , C12N2320/32 , C12N2320/35
摘要: The present embodiments provide methods, compounds, and compositions useful for inhibiting ENaC expression, which may be useful for treating, preventing, or ameliorating a disease associated with ENaC.
-
8.
公开(公告)号:US20240325568A1
公开(公告)日:2024-10-03
申请号:US18580716
申请日:2022-07-20
发明人: Benjamin Deverman , Qin Huang , Ken Chan
IPC分类号: A61K48/00 , A61K31/7105 , A61K38/46 , A61K47/64 , C12N15/86
CPC分类号: A61K48/0033 , A61K31/7105 , A61K38/465 , A61K47/64 , C12N15/86 , C12N2750/14122 , C12N2750/14143 , C12N2750/14145
摘要: Highly selective targeting moieties and compositions comprising the targeting moieties are described herein to efficiently transduce endothelial cell of the central nervous system vasculature. Embodiments include use and delivery of the targeting moieties and compositions to selectively direct delivery of cargo.
-
9.
公开(公告)号:US20240325308A1
公开(公告)日:2024-10-03
申请号:US18293419
申请日:2022-08-03
IPC分类号: A61K9/127 , A61K31/7105 , G01N33/50
CPC分类号: A61K9/1271 , A61K31/7105 , G01N33/5026 , G01N33/5076
摘要: The present disclosure relates, in part, to lipid nanoparticles (LNPs), and compositions comprising the same, which have increased stability in amniotic fluid, and methods of use thereof for in utero delivery of therapeutic agents, to treat and/or prevent diseases and/or disorders in a fetal subject. The present disclosure further relates to an ex vivo assay for screening LNP stability in a test fluid.
-
公开(公告)号:US12102649B2
公开(公告)日:2024-10-01
申请号:US17769986
申请日:2020-10-22
申请人: AIM ImmunoTech Inc.
发明人: Thomas K. Equels , David R. Strayer
IPC分类号: A61K31/7105 , A61K9/00 , A61K31/713 , A61K35/17 , A61P15/00
CPC分类号: A61K31/7105 , A61K9/0024 , A61K35/17 , A61P15/00 , A61K31/713
摘要: Disclosed is a method for treating endometriosis, preventing endometriosis, or ameliorating a symptom of endometriosis in a subject comprising the step of administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising as an active ingredient a therapeutic dsRNA (tdsRNA).
-
-
-
-
-
-
-
-
-